Fintech start-up Walletmor has confirmed the safety of its payment implant with further scientific research. The latest tests carried out by Konmex BioLabs confirmed the implant does not exhibit cytotoxic properties and can be perminantly implanted e.g. in subdermal fascia tissue (under the skin). Tests were conducted in accordance with bio-compatibility standards ISO 10993-5:2009E (cytotoxicity) and 10993-12:2021E. Walletmor plans further testing and international certification of its implant.
The management of London-based Walletmor Ltd is delighted to announce the introduction of the new generation implants, which will be valid for eight years at the same price of 199 euros. What is more, the 2-year valid implants will be available at 99 euros.
The latest innovative solution for contactless payments, the subdermal implant of the British company Walletmor, is rapidly gaining Poles interest. Following the curiosity of the media, banks and potential customers - users, a nationwide network of surgeries cooperating with Walletmor, ready to receive people interested in implantation is growing. According to the doctors, the procedure itself, performed in hygienic conditions, is safe, swift and painless.